1. Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting 
Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois, Chloé Chaulet, Jean-Louis Laplanche, Katell Peoc’h, Susanna Schraen, Florence Pasquier, Jacques Touchon, Jacques Hugon, Sylvain Lehmann, Audrey Gabelle 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 
Volume 9, Issue 4, Pages (July 2013)
DOI: /j.jalz
Copyright © 2013 The Alzheimer's Association Terms and Conditions

2. Fig. 1
Receiver–operator characteristics. (A–C) Cerebrospinal fluid (CSF) biomarkers of subjects with Alzheimer’s disease (AD; n = 515) were compared with a group of subjects without AD (n = 365) in the three centers. Abeta 1-42, amyloid beta 1–42; AUC, area under the curve; pTau, phosphorylated tau.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, DOI: ( /j.jalz )
Copyright © 2013 The Alzheimer's Association Terms and Conditions

3. Fig. 2
For the test–retest study, 32 cerebrospinal fluid (CSF) samples were measured repeatedly for biomarkers in each of the three centers using the same enzyme-linked immunosorbent assay batch for amyloid beta (Aβ) 1–42, tau, and phosphorylated tau (pTau-181), measured in pictograms per milliliter. The Bland–Altman plots show the differences in measures (ordinate) against their mean value (ordinate). Ninety-five percent limits of agreement are represented in ordinate (gray area).
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, DOI: ( /j.jalz )
Copyright © 2013 The Alzheimer's Association Terms and Conditions